CHMP recommends Rayvow , a serotonin (5-HT) 1F receptor agonist to treat migraine.- Eli Lilly
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rayvow (Reyvow in US), intended for the treatment of migraine.
The applicant for this medicinal product is Eli Lilly Nederland B.V.
Rayvow will be available as 50 mg, 100 mg and 200 mg film-coated tablets. The active substance of Rayvow is lasmiditan, a serotonin (5-HT) 1F receptor agonist (ATC code: N02CC), effecting a decrease of neuropeptide release and an inhibition of pain pathways. The benefits of Rayvow is its ability to reduce migraine pain. The most common side effects are dizziness, somnolence and fatigue.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.